Understanding drug resistance in malaria treatments in Kinshasa, DRC
Official title: Characterization of the antimalarial drug resistance landscape in Kinshasa Province, Democratic Republic of the Congo
Funded at Univ of North Carolina Chapel Hill · NIH-11058346 · Data updated 2026-11-12
This study is looking into how misdiagnosing malaria in Kinshasa might be making treatments less effective and leading to drug resistance, so we can find better ways to help people with malaria in areas where it's a big problem.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $44,012 |
| NIH project number | 5F30AI179110-02 |
| Project ID | NIH-11058346 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living in Kinshasa, DRC, who are affected by malaria or are at risk of infection.
✕Less likely to help
Patients living outside of the Democratic Republic of the Congo or those not affected by malaria may not benefit from this research.
What this research studies
This research investigates the growing issue of drug resistance to antimalarial treatments in Kinshasa, Democratic Republic of the Congo. It focuses on understanding how misdiagnosis of malaria affects treatment outcomes and contributes to drug resistance. By analyzing data and samples from a previous cohort study, the research aims to identify the extent of resistance to current first-line treatments and the factors influencing it. This information is crucial for improving malaria treatment strategies and control efforts in high-burden regions.
Why it matters
Potential benefit: If successful, this research could lead to more effective malaria treatment protocols, ultimately reducing morbidity and mortality associated with the disease.
How similar studies have gone: Previous research has shown that understanding drug resistance patterns can significantly improve treatment outcomes, indicating that this approach has potential for success.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Francois, Ruthly — Univ of North Carolina Chapel Hill
- Study coordinator: Francois, Ruthly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.